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Friedreich ataxia is an autosomal recessive, inherited neuro- and cardio-degenerative disorder char-
acterized by progressive ataxia of all four limbs, dysarthria, areﬂexia, sensory loss, skeletal deformities,
and hypertrophic cardiomyopathy. Most disease alleles have a trinucleotide repeat expansion in the ﬁrst
intron of the FXN gene, which decreases expression of the encoded protein frataxin. Frataxin is involved
in iron–sulfur-cluster (ISC) assembly in the mitochondrial matrix, and decreased frataxin is associated
with ISC-enzyme and mitochondrial dysfunction, mitochondrial iron accumulation, and increased
oxidative stress. To assess the role of oxidative stress in lipid peroxidation in Friedreich ataxia we used
the novel approach of treating Friedreich ataxia cell models with polyunsaturated fatty acids (PUFAs)
deuterated at bis-allylic sites. In ROS-driven oxidation of PUFAs, the rate-limiting step is hydrogen
abstraction from a bis-allylic site; isotopic reinforcement (deuteration) of bis-allylic sites slows down
their peroxidation. We show that linoleic and α-linolenic acids deuterated at the peroxidation-prone bis-
allylic positions actively rescue oxidative-stress-challenged Friedreich ataxia cells. The protective effect of
the deuterated PUFAs is additive in our models with the protective effect of the CoQ10 analog idebenone,
which is thought to decrease the production of free radicals. Moreover, the administration of deuterated
PUFAs resulted in decreased lipid peroxidation as measured by the ﬂuorescence of the fatty acid analog
C11-BODIPY (581/591) probe. Our results are consistent with a role for lipid peroxidation in Friedreich
ataxia pathology, and suggest that the novel approach of oral delivery of isotope-reinforced PUFAs may
have therapeutic potential in Friedreich ataxia and other disorders involving oxidative stress and lipid
peroxidation.
& 2013 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-ND license. Introduction
The clinical presentation, molecular genetics, and pathogenesis
of Friedreich ataxia are the subjects of several excellent recent
reviews [1–5]. Brieﬂy, Friedreich ataxia is the most common
hereditary ataxia, with a prevalence of approximately 1 in 50,000B.V.
NS, central nervous system;
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Open access under CC BY-NC-NDin European populations. The neurological signs and symptoms,
comprising ataxia, dysarthria, areﬂexia, and sensory loss, are largely
secondary to degeneration of the large sensory neurons of the
dorsal root ganglia and spinocerebellar tracts. Onset of symptoms
usually occurs around puberty and most patients are conﬁned to a
wheelchair by their late 20s. Myocardial failure and/or arrhythmias
are the most common cause of premature death. Currently, there
are no approved drugs to treat Friedreich ataxia and the resultant
disability, prolong the life of a Friedreich ataxia patient, or cure the
disorder.
The Friedreich ataxia disease protein, frataxin, localizes to the
mitochondrial matrix where it binds iron and is involved in iron–
sulfur-cluster (ISC) assembly [6,7]. ISCs are prosthetic groups impor-
tant for the function of many proteins, both mitochondrial and
cytosolic, including aconitase and mitochondrial respiratory com-
plexes I, II, and III. The decrease in frataxin function in Friedreich
ataxia results in decreased ISC assembly; in Friedreich ataxia
patients, as well as in yeast and mouse models, this is associated
with mitochondrial dysfunction, mitochondrial iron accumulation,
cytosolic iron depletion, and increased oxidative stress [8–22]. license. 
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subject of an excellent recent review by Armstrong et al. [23] That
there should be oxidative stress in Friedreich ataxia, and that it
might be difﬁcult to measure directly, is unsurprising. The iron
that accumulates in the mitochondria of cells with decreased
frataxin function is primarily ferrous. Ferrous iron can generate
toxic reactive oxygen species (ROS) through Fenton and related
Haber–Weiss reactions [24], initiating detrimental processes such
as lipid peroxidation [25,26]. The mitochondrial inner membrane
is particularly susceptible to lipid peroxidation due to the high
content of polyunsaturated fatty acids (discussed in detail below),
and lipid peroxidation is thought to play an important role in
neurodegenerative disease generally [27]. However, a certain level
of physiologic ROS is present normally, which can obscure low-
level signals from a relatively small number of affected disease
cells (such as in Friedreich ataxia), and cells with extremes of
oxidative stress often die by apoptosis. The preponderance of
evidence, both direct and indirect, supports the hypothesis that
oxidative stress contributes to Friedreich ataxia pathophysiology.
Nevertheless, the success of antioxidant-based therapies has
been limited, for Friedreich ataxia and for other disorders, for
several possible reasons, including lack of penetration across the
blood-brain barrier, the near-saturating amount of antioxidants
already present in living cells, the importance of ROS in cell
signaling, hormetic up-regulation of protective mechanisms, and
the potential toxicities of some antioxidants [28–36]. For example,
tocopherols (vitamin E) can have both anti-oxidant and pro-
oxidant effects [28]; such dual effects can depend on whether
physiologic or supra-physiologic levels are achieved [36]. Idebe-
none, a short-chain parabenzoquinone derivative with a structure
very similar to that of Coenzyme Q10 (CoQ10), advanced to phase
III trials for Friedreich ataxia. Like CoQ10, idebenone transfers
electrons from complex I and complex II to complex III in the
mitochondrial electron transport chain [37]. Both open trials, and
small double-blind placebo-controlled trials, indicated some indir-
ect evidence for efﬁcacy of idebenone for the cardiomyopathy of
Friedreich ataxia, but little evidence for efﬁcacy for the ataxia
of Friedreich ataxia [30–32,34]. In phase III trials of idebenone,
and in open-label extension studies, there were trends towardFig. 1. (A) ROS-driven oxidation of PUFAs. The rate-limiting step is ROS-driven hydroge
carbonyl compounds such as malondialdehyde and 4-hydroxynonenal, which irreversibl
acid are the n-6 and n-3 essential PUFAs fromwhich all higher PUFAs can be built. CNS ti
linoleic acid, is vital for mitochondrial function and, upon oxidation, plays a key role in a
the chemical nature of linoleic acid (D2-Lin) and α-linolenic acid (D2-Lnn), slows downimprovement in ataxia-scale scores and cardiac hypertrophy, but
statistical signiﬁcance was not achieved [38–40].
Polyunsaturated fatty acids (PUFAs) such as linoleic acid (C18:2,
n-6) and α-linolenic acid (C18:3, n-3) are essential fatty acids [41]
from which all higher PUFAs can be built [42,43]. CNS tissues are
rich in PUFAs [44]; the mitochondrial phospholipid cardiolipin,
which contains linoleic acid, is vital for mitochondrial function
and, upon oxidation, plays a key role in apoptosis [45]. In addition
to their vital role in lipid membranes, PUFAs are easy targets for
ROS in Friedreich ataxia due to the vicinity of ROS formation
(at the ISC-containing mitochondrial membrane proteins) to the
PUFA-rich mitochondrial membranes. PUFA autoxidation is a chain
reaction initiated by ROS whereby a small number of ROS can
damage a large number of PUFA molecules before the process is
terminated [46], changing the membrane ﬂuidity [47] and yielding
a wide array of lipid autoxidation products, such as toxic α,β-
unsaturated carbonyls like malondialdehyde, 4-hydroxynonenal,
and acrolein [48], which cannot be neutralized by simple chain-
termination strategies (Fig. 1A).
The excess mitochondrial iron associated with Friedreich ataxia
can catalyze the generation of hydroxyl radicals, which are so
reactive that they cause oxidative damage, such as initiation of
PUFA autoxidation, at their diffusion rate. Once lipid peroxides are
formed, iron can further accelerate their decomposition, which,
followed by β scission, gives rise to the whole smorgasbord of toxic
carbonyls, as described above [48]. For the reasons speciﬁed above,
in addition to a particularly high activity of the hydroxyl radical,
which is a function of its diffusion rate, conventional antioxidants
are not viable as a counteracting strategy and novel approaches to
the inhibition of lipid peroxidation processes are required. It is in
this context that we have proposed a novel lipid isotope stabiliza-
tion strategy, which employs the isotope effect to inhibit lipid
peroxidation [49–51]. In ROS-driven oxidation of PUFAs, the rate-
limiting step is hydrogen abstraction from a bis-allylic site;
isotopic reinforcement (deuteration) of bis-allylic sites, while not
changing the chemical nature of linoleic acid and α-linolenic acid,
slows down their peroxidation (Fig. 1B). Isotopically reinforced
linoleic acid and α-linolenic acid (Fig. 1C) provide a tool to
further assess the hypothesis that oxidative stress, particularlyn abstraction from a bis-allylic site. The end products of peroxidation are reactive
y damage proteins and DNA by forming cross-links. (B) Linoleic acid and α-linolenic
ssues are rich in PUFAs; the mitochondrial phospholipid cardiolipin, which contains
poptosis. (C) Isotope protection (deuteration) of bis-allylic sites, while not changing
their peroxidation.
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ogy, and to preliminarily assess whether dietary supplementation
with isotope-reinforced PUFAs might have therapeutic potential in
Friedreich ataxia. Thus, we sought to determine whether isotopi-
cally reinforced PUFAs are protective in oxidative-stress-challenged
Friedreich ataxia cells.0
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Fig. 2. (A) In yeast lacking Yfh1p, deuteration of PUFAs alleviates toxicity. Cells
were incubated in the presence of vehicle control (VC), linoleic acid (Lin),
α-linolenic acid (α-Lnn), or their corresponding deuterated forms (D-Lin, D-α-
Lnn); grown overnight, and plated at three different dilutions (1:20, 1:400, 1:1200).
Yeast cells incubated in the presence of linoleic acid or α-linolenic acid exhibited
signiﬁcantly less growth compared to cells incubated with their corresponding
deuterated forms (D-Lin, D-α-Lnn; row 2 vs. row 4, and row 3 vs. row 5,
respectively). (B) In yeast lacking Yfh1p, deuteration of PUFAs decreases lipid
peroxidation. Cells were incubated for 2 h in the presence of vehicle control (VC),
linoleic acid (Lin), α-linolenic acid (α-Lnn), or their corresponding deuterated forms
(D-Lin, D-α-Lnn) and then treated with C11-BODIPY (581/591) dye at 8 μM for
30 min at room temperature. Fluorescence was measured on a plate reader using
485/20 (excitation) and 520/20 (emission) ﬁlters and normalized by cell density
(optical density at 630 nm). Data are represented as the percentage of lipid
peroxidation relative to vehicle control (VC). nn, po0.005 by two-sided t-test.
The data shown are the mean and the standard deviation calculated from three
independent replicates.Materials and methods
Deuterated poly-unsaturated fatty acids (D-PUFAs)
11, 11-D2-linoleic acid and 11,11,14,14-D4-α-linolenic acid were
prepared as described previously [49] and used as free acids. Non-
deuterated PUFAs were obtained from Sigma-Aldrich (99%; St.
Louis, MO, USA).
Friedreich ataxia cell models
Frataxin and Yfh1p, the yeast frataxin homolog, are functional
homologs [9], and virtually every ﬁnding in yeast models of
Friedreich ataxia has been conﬁrmed in conditional knockout
mice, primary human ﬁbroblasts, and patients with Friedreich
ataxia. The yeast model of Friedreich ataxia used in this study lacks
the Yfh1 gene completely (Δyfh1::HIS3) and is derived from the
wild-type strain BY4741 (MATa leu2Δ0 met15Δ0 ura3Δ0 his3Δ1).
Yeast were grown in standard, Yeast-extract Peptone Dextrose
(YPD), medium. To test the effects of PUFAs and D-PUFAs on yeast,
cells were grown to early log phase, washed twice with water,
resuspended in 0.1 M phosphate buffer at pH 6 supplemented
with 0.2% glucose, and incubated in the presence of vehicle control
(ethanol) or PUFAs at a ﬁnal concentration of 200 μM for 4 h. The
cells were then resuspended in medium, allowed to grow over-
night, and spotted on solid medium at dilutions of 1:20, 1:400, and
1:1200. To detect lipid peroxidation, yeast cells were grown and
incubated with H- or D-PUFAs for 2 h as described above. Cells
were then treated with C11-BODIPY (Molecular Probes, Eugene,
OR, USA) at 8 μM ﬁnal concentration for 30 min at room tempera-
ture. Fluorescence was measured on a BioTek plate reader using a
485/20 excitation ﬁlter and a 520/20 emission ﬁlter and normal-
ized for the number of cells (optical density at 630 nm) [52,53].
The murine Friedreich ataxia cell model used in this study was
developed by Puccio and colleagues [54], and is a ﬁbroblast cell
line in which both alleles encoding murine frataxin are deleted
and replaced by human frataxin harboring the disease-associated
missense mutation, I154F. This model exhibits virtually all of the
biochemical hallmarks of Friedreich ataxia, including mitochon-
drial iron accumulation, loss of iron–sulfur-cluster-enzyme activ-
ities, and sensitivity to iron and oxidative stress. The human
Friedreich ataxia cells used in this study are primary human
Friedreich ataxia ﬁbroblasts (Coriell designation GM3665) with
GAA repeat expansions of 790 and 1357 repeats in the ﬁrst intron
of the Friedreich ataxia disease gene. Relative to control cells
(murine ﬁbroblasts in which murine frataxin is replaced by wild-
type human frataxin; primary human ﬁbroblasts), both mamma-
lian Friedreich ataxia models show increased sensitivity to
treatment with iron, as ferric ammonium citrate (FAC), and
L-buthionine (S,R)-sulfoximine (BSO), which inhibits the rate-
limiting step of glutathione synthesis. We have established con-
ditions under which concentrations of iron and BSO, that by
themselves are non-toxic, together cause a synergistic loss of
viability [55]. In addition, in validation experiments using drugs
currently in clinical trials for Friedreich ataxia, we have shown that
these assays have excellent sensitivity and dynamic range, and
allow a precise quantitative assessment of dose-response [55,56].
Brieﬂy, cells were grown in standard Dulbecco's modiﬁed Eagle'smedium (DMEM) with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin. For the murine ﬁbroblasts, 12,000 cells/
well were seeded into 48-well microtiter plates and FAC (F-5879,
Sigma, St. Louis, MO, iron content 16.5–18.5%) was added to a ﬁnal
concentration of 20 μg/mL (Day 0). The following day (Day 1), BSO
was added to a 50 μM ﬁnal concentration, and 2 h later compounds
(or vehicle alone) were added. Forty-eight hours later (Day 4), the
cells were washed with phosphate-buffered saline (PBS) and
viability was assessed by chemiluminescence measurement of
intracellular ATP using the CellTiter-Glo assay kit (Promega,
Madison, WI) as per the manufacturer's instructions. The human
ﬁbroblasts were tested similarly, except they were seeded at 3000
cells/well in 96-well plates, compounds were added 2 h after the
addition of FAC, BSO was added on Day 2, and viability was
quantiﬁed on Day 3. To detect lipid peroxidation, cells were
treated with FAC and BSO as described above, washed with PBS
and incubated with C11-BODIPY 581/591 at a ﬁnal concentration
of 8 μM for 3 h at 37 1C. Fluorescence was measured on a BioTek
plate reader using a 485/20 excitation ﬁlter and a 520/20 emission
ﬁlter. Cell viability was assessed in parallel lanes as described
above and used to normalize the ﬂuorescence values.
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We ﬁrst tested whether a yeast strain lacking the Yfh1 gene is
susceptible to PUFA-induced loss of viability and whether deutera-
tion of the PUFAs can reverse this effect. Yeast cells lacking Yfh1,
and the corresponding wild-type strain, were incubated in the
presence of vehicle control (ethanol), linoleic acid, α-linolenic acid,
or their corresponding deuterated forms (D-linoleic acid or D-α-
linolenic acid, respectively), at a ﬁnal concentration of 200 μM for
4 h (Section Materials and methods). The cells were then resus-
pended in medium, allowed to grow overnight, and spotted on
solid medium at three different dilutions. Yeast cells incubated in
the presence of linoleic acid or α-linolenic acid exhibited signiﬁ-
cantly less growth compared to cells incubated with D-linoleic
acid or D-α-linolenic acid, whereas there was no effect on the
viability of the wild-type strain used as a control (Fig. 2A). To test
whether treatment with PUFAs also affects lipid peroxidation,
yeast cells lacking Yfh1 were incubated with H- or D-PUFAs for
2 h and then treated with the ﬂuorescent fatty acid analog
C11-BODIPY, a sensitive indicator of lipid peroxidation and anti-
oxidant efﬁcacy in membrane systems and living cells. Oxidation
of C11-BODIPY (581/591) induces a ﬂuorescence shift from read to
green [57]. Although the ﬂuorescence does not yield strictly
quantitative information about lipid peroxidation, it does provide0
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Fig. 3. D-PUFAs are protective in the murine ﬁbroblast, I154F missense-mutation model
and treated with a combination of FAC (ferric ammonium citrate) and BSO (L-buthionine
addition; and viability was assessed by chemiluminescence measurement of intracellula
untreated control cells. The ﬁnal concentration of the drug vehicle (ethanol) was 0.5
independent replicates. (A) H-linoleic acid, H-α-linolenic acid, D-linoleic acid, and D-α-li
Treated (with FAC and BSO); VC, Vehicle Control; nnn, po0.001 by two-sided t-test. (B)
the viability of the cells treated with vehicle control only. (C) Dose response with H-α-li
cells treated with vehicle control only.a sensitive readout of radical processes that oxidize lipids in
membranes [58]. Treatment with D-PUFAs resulted in 25% and
45% decreased lipid peroxidation for D-linoleic acid and D-α-
linolenic acid, respectively (Fig. 2B). Treatment with H-α-
linolenic acid also resulted in a statistically signiﬁcant reduction
of lipid peroxidation, reﬂecting perhaps a non-speciﬁc beneﬁt that
the yeast cells gain by having a poly-unsaturated fatty acid in their
membranes. D-PUFAs also decreased lipid peroxidation in wild-
type yeast cells that were oxidatively stressed with 50 μM CuS04
(data not shown).
We then tested the effects of H- and D-PUFAs using the murine
ﬁbroblast, I154F missense-mutation model of Friedreich ataxia.
These cells are sensitive to the combination of iron (as FAC) and
BSO (which inhibits glutathione synthesis) at concentrations that
by themselves are non-toxic but together cause a synergistic loss
of viability. In Fig. 3A, we show that both D-linoleic acid and D-α-
linolenic acid rescue these cells from loss of viability at 16 μM
(po0.001) similarly to 1 μM idebenone, the CoQ10 analog tested
in drug trials for Friedreich ataxia. In Fig. 3B we show that as
concentrations were increased, H-linoleic acid became more and
more toxic in the presence of FAC and BSO, whereas D-linoleic acid
continued to rescue at 50 μM. Likewise, in Fig. 3C, we show that as
concentrations were increased, H-α-linolenic acid became more
and more toxic in the presence of FAC and BSO, whereas D-α-0
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of Friedreich ataxia, whereas H-PUFAs are toxic. Cells were seeded in 48-well plates
(S,R)-sulfoximine) for 72 h and 48 h, respectively; PUFAs were added 2 h after BSO
r ATP (Materials and Methods). The data represent the percent survival relative to
%. The data shown are the mean and the standard deviation calculated from six
nolenic acid were tested at 16 μM, and idebenone (IDB) was tested at 1 μM. NT, Not
Dose response with H-linoleic acid and D-linoleic acid, with survival normalized to
nolenic acid and D-α-linolenic acid, with survival normalized to the viability of the
M.G. Cotticelli et al. / Redox Biology 1 (2013) 398–404402linolenic acid continued to rescue at 80 μM. Using the same model,
we tested whether the effects of the D-PUFAs and idebenone were
additive, which would be consistent with different mechanisms of
action. Fig. 4 shows that at concentrations of D-linoleic acid and
D-α-linolenic acid that were only marginally protective (1.6 μM),
the addition of idebenone, also at a marginally effective concen-
tration (100 nM), resulted in an additive protective effect.
We then tested the effects of H- and D-PUFAs using primary
human Friedreich ataxia ﬁbroblasts. These cells are also sensitive
to the combination of iron (as FAC) and BSO (which inhibits
glutathione synthesis) at concentrations that by themselves are
non-toxic but together cause a synergistic loss of viability.
In Fig. 5A, we show that both D-linoleic acid and D-α-linolenic
acid rescue these cells from loss of viability at 10 μM (po0.001),
similarly to 1 μM idebenone. In Fig. 5B we show that as concen-
trations were increased, H-linoleic acid became more and more
toxic in the presence of FAC and BSO, whereas D-linoleic acid
continued to rescue at 80 μM. Likewise, in Fig. 5C, we show that as
concentrations were increased, H-α-linolenic acid became more
and more toxic in the presence of FAC and BSO, whereas D-a-
linolenic acid continued to rescue at 80 μM.
Lipid peroxidation in the membranes of primary human Frie-
dreich ataxia ﬁbroblasts (Coriell designation GM3665) was mon-
itored using C11-BODIPY (581/591). The ﬁbroblasts were stressed
with iron plus BSO and treated with PUFAs as described above and
then incubated with the C11-BODIPY. Lipid peroxidation in the cells
treated with FAC and BSO increased 2.5 fold relative to cells treated
with vehicle control alone and was unchanged by the addition of H-
PUFAs. In contrast, treatment with D-PUFAs resulted in signiﬁcantly
lower levels of lipid peroxidation (Fig. 6). We also tested the effects
of H- and D-PUFAs on both the mouse and human FA-cell models in
the absence of any exogenous oxidative stress; neither the H-PUFAs
nor the D-PUFAs affected cell viability up to 80 μM and 72 h of
treatment (data not shown).0
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Fig. 4. Additive effects of D-PUFAs plus idebenone on I154F cells treated with FAC+BSO.
as described in Fig. 3A. Two hours after the addition of BSO, the cells were treated with i
acid (D-α-Lnn; columns 7, 8) at two different concentrations, or a combination of ideben
concentrations indicated. After 2 more days, cells were lysed and their viability assesse
percent survival relative to untreated control cells. Drug vehicle (VC, ethanol) ﬁnal
concentration used (two sided p value po0.001, column 4 vs. column 2 cells treated wit
the cells only when used at 16 μM but not when used at 1.6 μM (columns 5 and 7 vs. 6 a
1.6 μM increased cell survival compared to cells treated with either idebenone or D-lino
cases). The combination of idebenone at 100 nM plus D-α-linolenic acid at 1.6 μM incr
linolenic acid alone (column 12 vs. column 4 or column 8; two-sided p values 0.001 and
independent replicates.Discussion
In our yeast model of Friedreich ataxia, the PUFAs linoleic acid
and α-linolenic acid were toxic in the micromolar range, and
deuteration of these PUFAs at bis-allylic sites eliminated the
toxicity. Our mammalian-cell models of Friedreich ataxia are
particularly sensitive to oxidative stress with FAC and BSO; in
both of these models, H-linoleic acid and H-α-linolenic acid in the
micromolar range signiﬁcantly exacerbated the toxicity of FAC and
BSO, whereas their deuterated counterparts, D-linoleic acid and
D-α-linolenic acid, were actively protective at the same concentra-
tions. H-linoleic acid and H-α-linolenic acid are known substrates
for PUFA-autoxidation chain reactions initiated by ROS, so their
toxicity in this context is not surprising. We expected that
replacement of bis-allylic hydrogen atoms in linoleic acid and α-
linolenic acid with the heavier stable isotope, deuterium (D),
would stabilize the C-H bond that is ﬁrst broken in lipid peroxida-
tion, thereby decreasing the formation of intracellular toxic lipid
peroxides and diminishing the activation of toxic cellular cascades.
Our results in Friedreich ataxia models are consistent with this
expectation, as well as with results in other disease models in
which oxidative stress is thought to play an important role [49–
51].
The signiﬁcance of our results is threefold: ﬁrst, while oxidative
stress in Friedreich ataxia has been difﬁcult to measure, the
protective effects of D-PUFAs in all three of our Friedreich ataxia
cell models indicate, directly in the yeast cells and indirectly in the
mammalian cells, that there is oxidative stress in these models and
emphasize the importance of lipid peroxidation. Second, our
results further support the proposal that reinforcing essential
PUFAs with isotopic replacement decreases lipid peroxidation
and decelerates toxic cellular cascades [59]. Third, together with
the results of Hill et al., who showed that substitution of as little as
20% of PUFAs with appropriately deuterated forms can be16 μM 1.6 μM 16 μM 1.6 μM 16 μM 1.6 μM
D-α-Lnn D-Lin D-α-Lnn
IDB 100 nM
FAC +BSO
Murine ﬁbroblast cells were seeded in 48-well plates and treated with FAC and BSO
debenone (IBD; columns 3, 4), D-linoleic acid (D-Lin; columns 5, 6), or D-α-linolenic
one and D-linoleic acid (columns 9, 10) or D-α-linolenic acid columns 11, 12), at the
d by chemiluminescence measurement of intracellular ATP. The data represent the
concentration was 0.5%. Idebenone (columns 3 and 4) was efﬁcacious at both
h FAC+BSO and no drug). D-linoleic acid and D-α-linolenic acid were able to rescue
nd 8, respectively). The combination of idebenone at 100 nM plus D-linoleic acid at
leic acid alone (column 10 vs. column 4 or column 6; two-sided po0.001 in both
eased cell survival compared to cells treated with either idebenone or with D-α-
0.0005, respectively). The means and standard deviations were calculated from six
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Fig. 5. D-PUFAs are protective in primary human Friedreich ataxia ﬁbroblasts oxidatively stressed with FAC and BSO, whereas H-PUFAs are toxic. Cells were seeded in 96-
well plates and treated with a combination of FAC (ferric ammonium citrate) and BSO (L-buthionine (S,R)-sulfoximine) for 96 h and 48 h, respectively; PUFAs were added
two hours after FAC addition; and viability was assessed by chemiluminescence measurement of intracellular ATP (Section Materials and methods). The data represent the
percent survival relative to untreated control cells. The ﬁnal concentration of the drug vehicle (ethanol) was 0.5%. The data shown are the mean and the standard deviation
calculated from six independent replicates. (A) H-linoleic acid, H-alpha-linolenic acid, D-linoleic acid, and D-α-linolenic acid were tested at 10 μM, and idebenone (IDB) was
tested at 1 μM. NT, Not Treated (with FAC and BSO); VC, Vehicle Control; nnn, po0.001 by two-sided t-test. (B) Dose response with H-linoleic acid and D-linoleic acid, with
survival normalized to the viability of the cells treated with vehicle control only. (C) Dose response with H-α-linolenic acid and D-α-linolenic acid, with survival normalized
to the viability of the cells treated with vehicle control only.
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Fig. 6. D-PUFAs decrease lipid peroxidation in primary human Friedreich ataxia
ﬁbroblasts oxidatively stressed with FAC and BSO. Cells were seeded in 96-well
plates and treated as described in Fig. 5. Fourty eight hours after the addition of
BSO, the cells were washed and treated with C11-BODIPY dye at 8 μM ﬁnal
concentration. In parallel lanes, cell viability was assessed by chemiluminescence
measurement of intracellular ATP (Section Materials and methods) and used to
normalize the ﬂuorescence values. The data represent the fold increase in
ﬂuorescence relative to untreated control cells. The data shown are the mean
and the standard deviation calculated from three independent replicates. The
PUFAs were tested at 16 μM. Lin, H-linoleic acid; α-Lnn, H-α-linolenic acid; D-Lin,
D-linoleic acid; D-α-Lnn, D-α-linolenic acid; NT, Not Treated (with FAC and BSO);
VC, Vehicle Control; nnn, po0.001 by two-sided t-test.
M.G. Cotticelli et al. / Redox Biology 1 (2013) 398–404 403protective [51], our results suggest that oral delivery D-PUFAs
might be an effective therapeutic strategy for the treatment of
Friedreich ataxia. A limitation of the present study is that the
primary intracellular location where D-PUFAs exert their protec-
tive effects in our models remains undeﬁned; however, given the
deleterious effects of frataxin mutations on the mitochondrial
electron transport chain, and the presence of mitochondrial iron
accumulation in Friedreich ataxia, it seems likely that the PUFA-
rich inner mitochondrial membranes are the primary site.Acknowledgments
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